NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
Universal mismatch repair (MMR) deficiency testing is widely recommended in patients with colorectal cancer (CRC) and others with a family history of MMR deficiency to identify Lynch syndrome, a ...
Roche announced US Food and Drug Administration (FDA) approval of the Ventana MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) ...
About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 ...
Please provide your email address to receive an email when new articles are posted on . Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced ...
A novel xenonucleic acid mediated molecular clamping technology for early colorectal cancer diagnostics. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--A new College of American Pathologists (CAP) evidence-based guideline is among the first to address testing based less on the cancer type or tumor origin and more on ...
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback